Smart Immune et CELLforCURE by SEQENS s'associent pour industrialiser la production des lots cliniques de SMART101 COMMUNIQUÉ DE PRESSE | Paris, France - 3 décembre 2024 Smart Immune, société de biotechnologie en stade clinique, et CELLforCURE by SEQENS, entreprise de développement et de fabrication en...

Smart Immune and CELLforCURE by SEQENS Partner to Industrialize SMART101 Clinical Batches Manufacturing PRESS RELEASE | Paris, France – December 3, 2024 Smart Immune, a clinical-stage biotechnology company, and CELLforCURE by SEQENS, a Contract Development and Manufacturing Organization (CDMO) for...

Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial PARIS, France, May 2, 2024 – Smart Immune, a clinical-stage biotechnology company developing...